Autonomix Medical, Inc.
1.0500-0.04 (-3.67%)
Oct 29, 4:00:02 PM EDT · NasdaqCM · AMIX · USD
Key Stats
Market Cap
6.50MP/E (TTM)
-Basic EPS (TTM)
-5.33Dividend Yield
0%Recent Filings
8-K
ATM offering expanded $1.4M
Autonomix Medical boosted its at-the-market offering agreement with Ladenburg Thalmann by $1.4 million on August 25, 2025, raising the total potential sales of common stock to $3.5 million. This expansion, under an effective S-3 shelf registration, provides flexible capital access amid the biotech's development push. Sales proceed through the agent as principal or otherwise. Yet funding remains pivotal for pipeline progress.
8-K
Autonomix secures $15M equity line
Autonomix Medical inked a $15 million equity line with Lincoln Park Capital on August 25, 2025, securing flexible funding over 24 months at discounted market prices, while issuing 261,932 commitment shares upfront. This bolsters working capital amid biotech volatility, yet Nasdaq caps limit issuances to 19.99% of outstanding stock without shareholder nod. Funds fuel operations.
10-Q
Q1 FY2026 results
Autonomix Medical posted a $3.3M net loss for Q1 FY2026 ended June 30, 2025, up 24% y/y from $2.7M, driven by 67% higher R&D spend on clinical trials while G&A held steady. Operating loss matched the net figure, with no material other items beyond $0.1M interest income. Cash burn quickened to $2.6M from operations, offset by $2.1M from ATM stock sales, leaving $8.6M on hand—enough into Q2 2026. The team advanced proof-of-concept studies for pancreatic pain tech and inked a royalty-free license for RF ablation gear in July 2024. Leadership shakeup followed, with execs canceling options for added severance. Cash stretches just far enough. Yet competition shadows clinical progress.
8-K
Warrant exercise yields $2.5M
Autonomix Medical induced holders of November 2024 warrants to exercise or prepay for 1,477,596 shares at a reduced $1.723 per share, netting up to $2.5 million in gross proceeds before fees. In exchange, the company issued new Series B warrants for the same number of shares at $1.723, exercisable over 5.5 years, while prepaid portions drop to $0.001. This bolsters working capital for general purposes. Post-deal, shares outstanding hit 4,877,625.
10-K
FY2025 results
Autonomix Medical, a development-stage medtech firm, posted FY2025 results reflecting intensified R&D efforts amid ongoing clinical progress, with no revenue yet from its neural sensing platform targeting pancreatic cancer pain. The company reported a net loss of $11.4 million, up from $15.4 million in FY2024, driven by $4.7 million in R&D expenses (112% y/y increase) tied to proof-of-concept trials and device refinements, while G&A rose 31% to $6.9 million on staffing and compliance costs; Q4 momentum showed accelerated trial execution in PoC 2, expanding to additional visceral cancers, though sequential quarterly breakdowns were not disclosed. Cash burn from operations hit $8.3 million annually, leaving $9.1 million in liquidity at year-end after a $10 million November offering, sufficient into Q1 2026 but signaling need for $32-40 million more to reach commercialization. No dividends or buybacks occurred, with capex minimal at $14,000. While PoC 1 yielded positive safety signals, regulatory hurdles loom large, as FDA acceptance of international data remains uncertain.
APYX
Apyx Medical Corporation
2.95-0.15
AXGN
AxoGen, Inc.
22.25+4.17
BSX
Boston Scientific Corporation
100.30-0.67
EMED
Electromedical Technologies, In
0.00+0.00
HSDT
Solana Company
6.78+0.17
NMTC
NeuroOne Medical Technologies C
0.79-0.03
NXL
Nexalin Technology, Inc.
1.55+0.07
OFIX
Orthofix Medical Inc.
15.32-0.70
PMI
Picard Medical, Inc.
3.28-0.77
RTGN
RETINALGENIX TECHNOLOGIES INC
3.75+0.00